A Multicenter Prospective Non-interventional Study Investigating the Treatment Effect of Xultophy Intensification in a Real World Population With Type 2 Diabetes in United Arab Emirates
Latest Information Update: 14 Mar 2023
At a glance
- Drugs Insulin degludec/liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms INTENSIFY
- Sponsors Novo Nordisk
Most Recent Events
- 01 Feb 2023 Results (n=263) assessing effectiveness of IDegLira, a fixed-ratio combination of insulin degludec/liraglutide, in a real-world setting in patients with type 2 diabetes mellitus in the United Arab Emirates published in the Diabetes Research and Clinical Practice
- 08 Feb 2021 Status changed from active, no longer recruiting to completed.
- 29 Sep 2020 Planned End Date changed from 25 Nov 2020 to 23 Dec 2020.